Our customer service representatives are available 24 hours a day, from Monday to Sunday.
| Catalog Number | CI-SC-0329 |
| Product Name | PEG-40 Stearate (CAS 9004-99-3) |
| CAS | 9004-99-3 |
| Description | PEG-40 Stearate is a type of emulsifying agent that is commonly used in skincare and cosmetic products. It is a blend of polyethylene glycol (PEG) and stearic acid, which helps to stabilize the ingredients in a formulation and prevent them from separating. PEG-40 Stearate also has emollient and moisturizing properties that help to hydrate the skin, making it a popular ingredient in creams, lotions, and emulsions. |
| Appearance | white waxy solid |
| Application | 1. Cosmetics: PEG-40 Stearate is widely used in cosmetics as an emulsifier and solubilizer. It helps blend different types of ingredients by creating a stable mixture and enhances the texture of the products. 2. Pharmaceuticals: It is used as an ingredient in certain topical ointments and creams to improve their consistency, texture, and to improve their ability to penetrate the skin. 3. Food Industry: PEG-40 Stearate is used as a food additive to improve the stability of oil-in-water emulsions, as well as in food packaging materials. 4. Industrial Applications: It is used in a number of industrial applications, including as a lubricant in the metalworking industry, in the production of adhesives, and as a dispersant for pigments and dyes. |
| Features And Benefits | 1. Emulsifying agent 2. Improves texture and consistency 3. Enhances spreadability 4. Solubilizes oils in water-based formulations 5. Provides moisturizing effects 6. Increases the stability of the finished product 7. Improves the efficacy of active ingredients in the formulation |
Fachinetti, Naiara, et al. AAPS PharmSciTech 19 (2018): 1401-1409.
Objective: To assess PEG-40 stearate as a lipid matrix for trans-resveratrol (RSV)-loaded nanostructured lipid carriers (NLCs) for skin-lightening purposes, and to compare the performance of NLCs in terms of encapsulation efficiency (EE), RSV release kinetics, and tyrosinase inhibitory activity against the hydrophobic glyceryl behenate.
Methods: NLCs were prepared by a high-shear homogenization technique at 70°C. Lipid phase: PEG-40 Stearate (contral: glyceryl behenate), caprylic/capric triglyceride, castor oil + 0.1% RSV; Aqueous phase: Poloxamer 407, preservatives, water. The mixture was homogenized at 10,000 rpm/10 min to create the emulsion, which was then subjected to ice-bath crystallization. The NLCs were evaluated for particle size, polydispersity (PDI), EE, DSC crystallinity analysis, RSV release, cytotoxicity assay (L-929 cells), and in vitro tyrosinase inhibition assay.
Key Results: The results demonstrated superior nanoparticle properties (smaller particle size, lower PDI) with PEG-40 Stearate NLCs compared to glyceryl behenate NLCs, allowing a greater RSV EE. Both NLCs formulations showed minimal RSV release over 72 h due to high lipid crystallinity (confirmed by DSC), and the PEG-40 Stearate NLCs demonstrated a significant increase in tyrosinase inhibition compared to the RSV solution (1.31×) and glyceryl behenate NLCs (1.83×), with no associated increase in cytotoxicity (L-929 cells).
Conclusion: PEG-40 Stearate was able to optimize the RSV delivery from NLCs for skin-lightening applications by providing smaller particle size, efficient drug encapsulation, and significantly improved tyrosinase inhibitory activity as compared to a hydrophobic lipid matrix alternative.
Cassano, Roberta, et al. Drug delivery 23.3 (2016): 1037-1046.
Objective: To develop and characterize PEG-40 Stearate-based solid lipid nanoparticles (SLNs) for controlled drug delivery of ketoconazole and clotrimazole against Candida albicans infections.
Methods:
· Chemical Modification: PEG-40 Stearate was acrylated (78% yield) via reaction with acryloyl chloride/triethylamine in dry THF (90°C), purified by silica chromatography, and validated by FT-IR/¹H-NMR.
· SLN Fabrication: Non-polymerized SLNs were prepared by microemulsion technique (70-75°C) using PEG-40 Stearate ± drug. Polymerized SLNs were prepared by acrylated PEG-40 stearate crosslinked to form a secondary shell.
· Process Details: Melted lipid + sodium taurocholate/Tween-20/butanol microemulsion dispersed in cold water (2°C) at 8,000 rpm (1:20 ratio), purified via ultrafiltration.
· Evaluation: Drug release profiles in C. albicans-simulated conditions; Minimal inhibitory concentration (MIC) tes.ting; In vitro permeability assessment at infection site.
Key Findings:
· Release Modulation: Acrylation enabled polymerization for sustained release via a secondary shell. Polymerized acrylate-SLNs demonstrated slower drug release vs. non-modified PEG-40 Stearate SLNs.
· Therapeutic Potential: SLNs enhanced drug permeability at the action site and showed efficacy against C. albicans in simulated vaginal environments.
Conclusion: PEG-40 Stearate serves as a versatile lipid matrix for vaginal antifungal SLNs. Its acrylation enables tunable drug release kinetics via polymerization, improving targeted delivery for C. albicans infections.
If you have any questions, please contact us. You will get a satisfactory answer.
